Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
The present invention, in some embodiments, generally relates to methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury. In some embodiments, the brain injury results from a hypoxic event. In some embodiments, methods are provided for determining a measure of the concentration of tau protein in a patient sample containing or suspected of containing tau protein.
1. A method of producing a bodily fluid sample of a patient suspected of having a neurological condition containing an analytically quantified amount of endogenous tau protein, said method comprising:
(A) obtaining a volume of bodily fluid comprising blood, or a blood component selected from plasma and serum,
(B) diluting the volume of bodily fluid, and
(C) quantifying through the use of an analytical protein concentration measurement assay a concentration of tau protein in the volume of bodily fluid to produce the bodily fluid sample containing the analytically quantified amount of endogenous tau protein;
wherein the analytically quantified concentration of endogenous tau protein contained in the bodily fluid sample is less than about 5 pg/nil, and a limit of quantification of the analytical protein concentration measurement assay used in step (C) for quantifying the concentration of tau protein is less than about 0.2 pg/mL.
2. The method of claim 1 , wherein the analytical protein concentration measurement assay used in step (C) comprises:
i. exposing a plurality of capture objects that each include a binding surface having affinity for tau protein molecules to the volume of bodily fluid;
ii. immobilizing at least a portion of the tau protein molecules with respect to the plurality of capture objects such that at least some of the capture objects associate with at least one tau protein molecule and a statistically significant fraction of the capture objects do not associate with any tau protein molecules;
iii. determining a proportion of the plurality of capture objects that associated with a tau protein molecule in step ii; and
iv. determining a measure of tau protein molecule concentration in the volume of bodily fluid based at least in part on the proportion determined in step iii.
3. The method of claim 2 , wherein the plurality of capture objects comprises a plurality of beads.
4. The method of claim 1 , wherein the analytical protein concentration measurement assay used in step (C) comprises spatially segregating tau protein molecules into a plurality of locations, wherein a statistically significant fraction of the locations contain a single tau protein molecule and a statistically significant fraction of the locations do not contain any tau protein molecules.
5. The method of claim 4 , wherein the plurality of locations comprises a plurality of reaction vessels.
6. The method of claim 1 , wherein each of the tau protein molecules quantified in step (C) is selected from the group consisting of tau 23 (352, 0N3R), tau 2.4 (383, 0N4R), tau 37 (381, 1N3R), tau 34 (412, 1N4R), tau 39 (410, 2N3R), and tau 40 (441, 2N4R).
7. The method of claim 6 , wherein at least a portion of the tau protein molecules are phosphorylated.
8. The method of claim 1 , wherein the volume of bodily fluid comprises blood.
9. The method of claim 1 , wherein the volume of bodily fluid comprises plasma.
10. The method of claim 1 , wherein the volume of bodily fluid comprises serum.
11. The method of claim 1 , wherein the volume of bodily fluid does not comprise cerebrospinal fluid (CSF).
12. The method of claim 1 , wherein the analytical protein concentration measurement assay used in step (C) comprises:
i. suspending a plurality of capture objects that each include a binding surface having affinity for tau protein molecules in the diluted volume of bodily fluid,
ii. immobilizing at least a portion of the tau protein molecules with respect to at least some of the plurality of capture objects suspended in the diluted volume of bodily fluid such that at least some of the capture objects associate with at least one tau protein molecule from the volume of bodily fluid,
iii. interrogating at least some of the capture objects associated with at least one tau molecule from the volume of bodily of fluid; and
iv. determining a measure of tau protein molecule concentration in the volume of bodily fluid based at least in part on the interrogating step performed in step iii.
13. The method of claim 12 , wherein the plurality of capture objects comprises a plurality of beads.
14. The method claim 1 , wherein the limit of detection for the analytical protein concentration measurement assay is less than about 0.02 pg/mL.
15. The method of claim 1 , wherein the patient suspected of having a neurological condition is recovering from a brain injury.
16. The method of claim 15 , wherein the volume of bodily fluid has been collected from the patient within 12 hours of the brain injury.
17. The method of claim 15 , wherein the brain injury results from a hypoxic event.
18. The method of claim 15 wherein the brain injury comprises a hypoxic event caused by cardiac arrest.
19. The method of claim 15 , wherein the brain injury comprises a hypoxic event caused by stroke.
20. The method of claim 15 , wherein the brain injury comprises a hypoxic event caused by an ischemic event.
21. The method of claim 15 wherein the brain injury comprises a hypoxic event caused by a thrombosis.